Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06217562 · ClinicalTrials.gov registry record · Phase 4
Vasopressin for Septic Shock Pragmatic Trial
A Phase 4 study of Septic Shock, sponsored by Intermountain Health Care.
- Active
- Registry status
- Phase 4
- Development phase
- 2,050
- Enrollment target
- 13
- Study locations
NCT06217562 is a Phase 4 study of Septic Shock that is active but no longer recruiting, run by Intermountain Health Care. The registered enrollment target is 2,050 participants, below the 4,974-participant average among 24 other Septic Shock trials with a reported enrollment target (59% lower). The trial reports 13 study locations across 2 states.
The verdict
NCT06217562, a Phase 4 study of Septic Shock, is active but no longer recruiting, sponsored by Intermountain Health Care.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,050 participants
- Enrollment target
- 13
- Study locations
Study Summary
Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.
Conditions Studied
Interventions
- DRUG Vasopressin
- OTHER Recommendation to use a lower initiation threshold for vasopressin
- OTHER Recommendation to use a higher initiation threshold for vasopressin
Study Locations (13)
Utah
- American Fork Hospital - American Fork
- Cedar City Hospital - Cedar City
- Layton Hospital - Layton
- Logan Regional Hospital - Logan
- Intermountain Medical Center - Murray
- McKay-Dee Hospital - Ogden
- Park City Hospital - Park City
- Utah Valley Hospital - Provo
- Riverton Hospital - Riverton
- LDS Hospital - Salt Lake City
- Alta View Hospital - Sandy City
- St. George Regional Hospital - St. George
Idaho
- Cassia Regional Hospital - Burley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,050 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06217562
The ClinicalTrials.gov registry entry for NCT06217562 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 2,050 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,974-participant average among 24 other Septic Shock trials with a reported enrollment target (59% lower). The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Septic Shock appearing as the primary indexed condition, and to 3 interventions - of which Vasopressin is the first listed.
NCT06217562 reports 13 study locations spanning 2 distinct geographic areas - top geographies include Utah, Idaho.
Frequently Asked Questions
What is clinical trial NCT06217562 about?
NCT06217562 is a clinical study titled "Vasopressin for Septic Shock Pragmatic Trial". Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, th...
What is the current status of trial NCT06217562?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2,050 participants. The study started on 2024-02-01. Estimated completion is 2027-12.
What conditions does trial NCT06217562 study?
This clinical trial studies the following conditions: Septic Shock.
What interventions are being tested in trial NCT06217562?
The interventions under investigation include: Vasopressin (DRUG), Recommendation to use a lower initiation threshold for vasopressin (OTHER), Recommendation to use a higher initiation threshold for vasopressin (OTHER).
Who is sponsoring clinical trial NCT06217562?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06217562 being conducted?
This trial has 13 study locations across Idaho, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Early Angiotensin II in the Emergency Department
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
COMPLETED · Phase 4
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.